关于金氏酸Rg2和Rh1对神经系统和相关机制的影响的研究进展
Silu Liu1, Weijia Chen1, Yan Zhao1
1College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Molecules (Basel, Switzerland)
|December 9, 2023
概括
从人参中获得的Rg2和Rh1类人参酶在治疗诸如阿尔茨海默病之类的神经系统疾病方面表现有前途. 这些化合物提供神经保护和认知效益,为传统药物提供更安全的替代品.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 草药是一种草药.
背景情况:
- 神经系统疾病,包括帕金森病 (PD) 和阿尔茨海默病 (AD),显著损害生活质量.
- 目前用于神经疾病的治疗方法通常会导致药物耐药性和器官功能障碍等不良影响.
- 迫切需要更安全,副作用更少的治疗药物.
研究的目的:
- 在神经疾病中审查人参化物Rg2和Rh1的药理作用和机制.
- 探索这些人参化合物的潜力,作为神经退行性疾病的新治疗方法.
- 总结最近关于Rg2和Rh1的神经学应用的研究进展.
主要方法:
- 关于人参酸Rg2和Rh1.1.的药理学研究的文献搜索.
- 对研究的分析,重点关注它们在神经疾病模型中的影响.
- 审查它们的神经保护和治疗作用背后的机制.
主要成果:
- 金色化物Rg2和Rh1具有显著的神经保护性.
- 这些化合物在改善记忆力,认知缺陷和治疗AD等疾病方面表现出有效性.
- 它们对神经元损伤,缺血/再输损伤以及因血栓性出血引起的脑损伤具有抗性.
结论:
- 金色化物Rg2和Rh1具有有益于神经健康的多种药理活动.
- 它们的神经保护和治疗潜力为开发用于治疗神经系统疾病的新药提供了有希望的途径.
- 这些发现强调了人参的活性成分作为新治疗策略的宝贵资源.
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Peripheral Nervous System: Ganglia and Nerves
1.9K
The Peripheral Nervous System (PNS) is a crucial component of the body's neural network, extending beyond the central nervous system (CNS) to bridge the gap between the CNS and the external environment. It encompasses nerves, ganglia, and sensory receptors.
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
1.9K
Sympathetic Signaling
967
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
967
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436


